ECoG timescales decrease during spatial attention. حسب Isabel Raposo (21615517)

"…The individual values for panel A and C are included in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003232#pbio.3003232.s005" target="_blank">S2 Data</a>, Experiment 1, 3 and 4 sheets and <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003232#pbio.3003232.s006" target="_blank">S3 Data</a>, respectively.…"

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  حسب Beatrice T. Nganso (4114768)

الموضوعات:

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. حسب Shuhuan Zhang (748003)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

HSP90 inhibition by RGRN-305 and 17-AAG decreased proinflammatory protein secretion. حسب Hakim Ben Abdallah (14578241)

Incorporating a social responsibility goal in the prompt causes overleverage in utilities (A) and decreases risk of low ESG rating (B) (Study 3). حسب Philipp Winder (21615570)

Naringenin decreases mitochondrial function. حسب Lauren A. Eanes (20995499)

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 ^a indicates ≥1.50 SD (17.9) from the mean (32.9... حسب Luke R. Cavanah (19022435)

Decreased cytokine expression in J2.2-HKU1.7b-infected BMDM. حسب Chaminda D. Gunawardene (22794593)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: